Platinum Priority – Editorial Referring to the article published on pp. 949–956 of this issue Prostate Cancer Progression: The Smoking Gun?

further evidence supporting an association of smoking with risk of clinical outcomes in men with prostate cancer. In prior studies, smoking has been associated with biochemi-cal recurrence (BCR), metastasis, hormone refractory prostate cancer, and prostate cancer mortality in patients receiving one type of treatment [2–6] and in studies adjusted for the type of treatment [7]. With 22 yr of follow-up among 5366 men with prostate cancer in the Health Professionals Follow-Up Study, we showed that current smoking was associated with a 61 % increased risk of BCR as well as a 61 % increased risk of prostate cancer mortality [7]. As with the current study, we did not observe an association between cumulative dose measured by pack-years for BCR, and also like Rieken et al [1], we found that smokers who had quit for 10 yr or more had similar risks a